It has been shown that the mechanism of ICI drug action is through blocking the interaction between the cell surface marker PD‐1 on T or B cell and its binding partner the PD‐L1 on the tumor cell, which subsequently causes the restoration of T cells (such as CD8+ T cell) proliferation then to resist the tumor‐induced immune inhibition.19 This evidence concerns the gene CD8A and neoplasm.